

PSYCHOPHARMACOLOGY

And Substance Abuse Newsletter

Division 28 - American Psychological Association

Spring 1995

Volume 28, No. 1



From the President's Desk ...

John Grabowski, Ph.D.
President, Division 28

First, an apology to those who await these missives with bated (or baited—odoriferous?) breath. This newsletter is uncharacteristically brief. Dr. Zacny required space for the APA Annual Meeting Program of Fine Events; we look forward to seeing you there and at the business meeting. I will return to reckless ramblings in what sadly will be my last column, unless there is a ground swell for institutionalization (of the column). There have been several additional distinguished volunteers since the last newsletter. If you wish to help with Division 28 activities, contact me at the numbers listed below.

APA Presidential Candidates

In the upcoming election for APA President, the Hare system requires rank ordering of candidates. Kurt Salzinger and Richard Suinn are two candidates who are particularly sensitive to the range of scientist, educator, and scientist practitioner issues represented by Division 28 and the APA as a whole. I recommend that you rank them in order, 1-Salzinger, 2-Suinn.

Peer Review at the NIH

Members of Division 28 and APA should be 'interested parties' regarding NIH goals and funding in terms of both scientific endeavor and ultimate benefit to patients. Recently, when the former ADAMHA Institutes (NIDA, NIAAA, and NIMH) were placed in NIH, the immediate disaster that had been

predicted was forestalled; but cataclysms are always possible.

Some were concerned about the reintegration of these institutes, others found it odd that mind and body had ever been separated. Unfortunately, while NIH has regained its 'mental health', these three institutes seemingly have vestigial status within an agency driven by molecular action. The problem is the apparent struggle with the concept of behavior as anything more than an epiphenomenal outgrowth of molecular activity. By way of example, we have found that advanced pharmacology graduate students may be unfamiliar with opiate withdrawal symptoms and that behavioral manifestations of drug action have little standing in this pervasive 'moleculology'. This gestalt may mean difficult times for grant applications exam-

ining whole organisms in psychopharmacology, behavioral pharmacology, substance abuse, or mental health.

NIDA, NIAAA, and NIMH grant applications are now subject to the NIH review procedures. In the new scheme, two divergent paths exist for review of applications submitted to NIDA, NIAAA, or NIMH. One is review of applications under the auspices of the Division of Research Grants at NIH. This includes possible review by large committees servicing multiple institutes (Muffler City compared to Mufflers by Mercedes). This would not be inherently bad if committee members followed recommendations of the main expert reviewers; but they do not. Applications characterized by interdisciplinary conceptualizations, along with integration of measures and technologies, reportedly fare poorly. Apparently, they offend all equally. The 'Behavioral Medicine' committee of NIH exemplified this problem for some years. Consisting of an expert from each of many different fields, it is said the committee had a difficult time reaching agreement with the result that promising work was buried in a box.

A variation on this theme would include

(cont'd, p. 2)

IN THIS ISSUE

In Brief Column	page 3
Convention Schedule: Division 28	page 4
More Convention Info	page 6

President's Letter, cont'd

committees with representatives of NIMH, NIAAA, and NIDA. Superficially, this is not a bad plan. Unfortunately, the experience of cross-over investigators in these fields (e.g. mental health, or alcohol abuse, or drug abuse) submitting to another institute (e.g. NIDA, NIMH, NIAAA) has not been good. It appears that speciation, ala Darwin's finches, has transpired during the separation of Drugs and Alcohol from Mental Health, precluding mating or successful progeny. This may abate as these Institutes find themselves confronted with the realities of NIH. (Recall the lore; warring countries of the world unite to save earth from marauding alien algae eaters). Whether or not such committees would succeed in supporting the best of science or emulate the Behavioral Medicine committee and macerate most applications is unclear. New, adaptive behaviors of reviewers and an even handed Senior Review Administrator ('executive secretary') would be essential.

The other path for applications will be Special Review Committees within Institutes paralleling the pre-merge system. This has prevailed during the transition; i.e. each Institute controlled its own committees. Now these will be operative only when the applications are responsive to specific announcements.

This requires effective development of requests for applications by Institute staff members. Then Special Review Committees will play an important role in sustaining continuity in the field and subspecialties. The effectiveness of this mechanism, and extent of its use, depends on the Institute administration. Equity demands proportional representation in terms of committees and announcements. Development of preferential funding of 'Neuro-, 'Molecular', or 'Imaging' science over traditional Psychopharmacology, Behavioral Pharmacology or Behavioral Biology, could easily result from issuance of many announcements in the former areas, and few in the others. The result would be special review committees for neuro-, molecular, or imaging science, while other proposals would be shunted to large, fractious committees in the NIH.

Inequity could produce a shift in the balance of funding, placing behavior in the domain

of Ridley's turtle. For those with alternative orientations and unfamiliar with Gulf wildlife, consider this parallel: molecular types believe that the function of a human is to produce sperm, or oval, DNA; humans are a nuisance delaying the expeditious study of l'eau de molecules. We are at best an irrelevant and fleeting 'quark of fate' to be tolerated. Alternatively, and a still more familiar analogy; a chicken is the egg's way of producing company. The shift of NIDA to a dominantly 'molecular' institute, bereft of behavior of intact humans and other organisms could be achieved intentionally or otherwise. Scientists, practitioners, NIDA administrators, and legislators with an interest in behavior of intact organisms (including their own) should actively assure balance.

The concerns emerge from the fact that NIDA is reformulating its review capability to comply with NIH guidelines and a superficial hat tipping to 'reinvention of government'. It will have one large chartered committee for special reviews conducted by 11 sub-committees. The most recent list appeared skewed in the direction of neuroscience, molecular activity, and imaging art forms, with these having 4 or 5 subcommittees, but with only 1 'behavioral science committee'; the others are spread across disciplines. For the neuroscientists licking their electrophoretic gels or mesmerized by colorful images, the proposal here is enlightened (vs. greedy) self-interest. There must be meaningful behavioral end points. Human kind does not survive by migrating molecules alone. In the end, fractionation of these difficult interdisciplinary areas of science could flip the circuit breaker on the enterprise. The recommendation is that we work together to educate our own colleagues, other groups at the NIH, and the broader public. Make of it what you will.

One final comment regarding review is directed at the young and eager. You will be told by disgruntled colleagues that the system is unfair, that the "good old boys" run the reviews, and there is no hope. Untrue. Speak with mentors and colleagues, call the Institutes and ask for technical assistance, respond to an announcement (see above), and write a terrific application. In spite of this and most important, when your terrific first

PSYCHOPHARMACOLOGY

And Substance Abuse Newsletter



Division 28 - American Psychological Association

EDITORIAL POLICY

Psychopharmacology and Substance Abuse Newsletter is a quarterly publication of Division 28 of the American Psychological Association. It is devoted to keeping its members informed about the activities of Division 28 and to the news and comments concerning all aspects of Psychopharmacology and Substance Abuse.

Comments, brief articles (1,000-2,000 words), and letters are welcome and will be considered for publication as space allows. Articles, comments, announcements, and advertisements should be sent to:

James P. Zacny, Ph.D.
Dept. of Anesthesia and Critical Care
University of Chicago
MC 4028
5841 S. Maryland Ave.
Chicago, IL 60637

Submissions should be submitted in both hard copy (letter quality) and diskette. FAX submissions are discouraged.

Deadlines are March 15 (Spring), June 15 (Summer), September 15 (Fall), and December 15 (Winter).

submission receives a 'less than fundable score' or, is 'triaged' and goes unscored in the new system, do not give up. Clean it up, respond positively to the critique, and resubmit (unless of course they tell you it is a really dumb idea—then you might consider alternatives). Expecting to receive a 1.0 on your first grant application is like—, like—, like, the economy. Think of preparation of the revision as an improved systematic replication. This will be true even in the reinvented government described in the "World According to Gore(p)". Again, make of it what you will.

Contact me at: (713) 792-7925, FAX (713) 794-1479 (one of the FAX numbers in the last newsletter is no longer correct—do it again if you did not get a response) or EMail:

jgrabows.UTMSMAIL
@msi66.msi.uth.tmc.edu

or via real letter at:
Substance Abuse Research Center, Dept of Psychiatry, University of Texas Health Science Center, 1300 Moursund, Houston Texas 77030.

IN BRIEF:

The goal of the "In Brief" column is to describe selected recent human and animal studies exploring topics potentially of broad interest to Division 28 members. This column describes a study which illustrates the generalizability of perhaps the oldest observation in behavioral pharmacology, the rate-dependency effects of drugs on behavior.

Research by Peter Dews of Harvard in the 1950s showed that effects of drugs on behavior depended on the rate of pre-drug baseline behavior. For example, amphetamine was shown to increase operant responding in animals engaging in low baseline rates of that behavior but to decrease responding in animals engaging in high baseline rates of that behavior. This finding, which called into question the standard classification of some drugs as "stimulants" or "depressants", was a catalyst in the birth of the field of behavioral pharmacology.

Despite the many replications and robustness of this finding in studies of operant responding, there have been relatively few investigations of the generalizability of "rate-dependency" to other types of drug effects. However, Richard Hughes and Michael Baker of Iowa State University recently reported in *Experimental and Clinical Psychopharmacology* (1995, vol. 3, pp. 3-8) that morphine's effect on nociception was dependent upon baseline responding on the test of nociception. Cockerel chicks ($n=96$) were randomized to 6 groups, 3 of which received handling and habituation pre-treatment ("H/H", known to increase nociception test responding) and 3 of which did not ("NH/NH"). This treatment manipulation was crossed with morphine test dose (0, 5, 10 mg/kg) to form a 2×3 factorial design. Handling and habituation treatment consisted of injecting chicks with saline and placing them in wood and Plexiglas "habituation" chambers for 30 min on each of 8 days. On Day 9, all chicks were injected i.p. with their assigned morphine dose and then placed in the habituation chamber (H/H) or returned to their home cage (NH/NH) for 30 min. Nociception was then tested in a separate chamber by s.c. formalin injection in the foot, which typically results in foot-lifting behavior, evidence of pain. Baseline responding on the nociception test was determined by the amount of responding in the 0mg morphine (i.e. vehicle) groups.

As expected, H/H pre-treatment doubled the number and quadrupled the duration of footlifts following vehicle, compared with NH/NH treatment, demonstrating successful manipulation of baseline responding. In H/H animals, morphine decreased footlifting frequency and duration in dose-dependent fashion (demonstrating hypoalgesia, or antinociception), as typically

observed in other animals. However, morphine ~~generally~~ increased footlifting (hyperalgesia) in NH/NH animals. Thus, morphine produced a decrease in pain-related behavior in animals with high baseline levels of this behavior but an increase in animals with low baseline levels, conceptually identical to the notion of baseline rate-dependent effects of drugs on conventional operant responding. The authors also noted the methodological importance of this finding, that the typical procedures of pre-treatment handling, etc. in analgesic studies with animals would foster high baseline responding on this commonly used nociception test, enhancing the hypoalgesic effect of morphine. Variability in this handling-within or between studies--could therefore lead to variability in the observed "analgesic" effect of drugs, complicating interpretation of findings.

There may be many other drug effects consistent with the notion of rate-dependency, such as lithium effects on normalizing mood in patients with bipolar disorder or the influence of nicotine on subjective arousal in smokers (i.e. anecdotal reports of "stimulating" and "calming" effects from tobacco smoking). Similar baseline-dependent effects may even be seen following non-drug manipulations (e.g. "Law of Initial Values" in psychophysiology). Greater appreciation of this venerable observation in behavioral pharmacology may reveal a "law" relevant to a broad spectrum of research in psychology.

In Memoriam

George Armstrong Heise (1924-1995)

George A. Heise died unexpectedly April 3, 1995 from complications which developed after he contracted a virus. He was 70.

Heise began his graduate career in biochemistry, but soon switched to experimental psychology, initially working in the area of sensation and perception. After receiving his PhD from Harvard University in 1952, Heise taught at Oberlin College, but soon left for Hoffman-LaRoche where he directed the behavioral pharmacology laboratory. He was responsible for much of the early behavioral work on the anxiolytic, chlordiazepoxide.

George missed teaching and left Hoffman-LaRoche for Haverford

College, but found the research opportunities there limited and so joined the faculty at Indiana University in 1964 where he remained, retiring in 1990. Most of Heise's research at Indiana focussed on discrete trial analysis of drug action and was characterized by meticulous attention to the stimulus and response events controlling responding on any particular trial. He drew our attention to the role of the animal's own behavior as a cue for responding through his analysis of cholinergic influence on go/no-go alternation and spatial alternation performance. His work was supported by grants from NIMH and, in the latter years, EPA, as he turned his attention to the influence of environmental toxins on animal memory.

Heise was a Fellow of Division 28 and served as its president as well as serving as president of the Behavioral Pharmacology Society.

I know I speak for most of his students, when I say that we consider ourselves fortunate to have had such a mentor. Some 15 students received graduate degrees under George's tutelage, and can be found in colleges, universities, medical schools and pharmaceutical companies. That count neglects the undergraduates and research assistants welcomed into his lab who, although they earned graduate degrees elsewhere, would count George as their mentor as well. His style of interaction—persistent, challenging, yet courteous—provided a model of intellectual discourse that demanded the utmost rigor, but fostered an atmosphere of mutual respect and inspired genuine affection. He will be greatly missed.

Katharine S. Milar
Professor of Psychology
Earlham College
Richmond IN 47374
KATHYM@EARLHAM.EDU

1995 APA Division 28 Convention

Program

Schedule

FRIDAY, AUGUST 11

8:00-8:50 am (Miller Room, Marriott)

Symposium: DoD psychopharmacology demonstration project: Perspectives on curriculum—past, present, future. 1. Historical perspectives—How the PDP came to be. (Col. Greg Laskow, PhD). 2. Current didactic and clinical practicum curriculum. (Col. Marvin Oleshansky, MD). 3. Role of DoD advisory council to the Assistant Secretary of Defense. (Col. Dennis J. Grill, PhD). 4. Training program completed, and you think you can prescribe? (Comm. John L. Sexton, PhD). Discussant: Patrick H. DeLeon, PhD, JD. Chair: Major Debra Dunivin, PhD.

9:00-9:50 am (Wilder/Odets Room, Marriott)

Solvay-Duphar Awardee Address: Antidepressant drug action: Fusion between clinical and laboratory research. (Lewis Seiden, PhD). Chairs: (Larry D. Byrd, PhD and Berend Olivier, PhD).

10:00-10:50 am (Booth/Edison Room, Marriott)

Young Psychopharmacologist Awardee Address: GABA_A receptor heterogeneity and behavior: Diazepam-insensitive benzodiazepine receptors (Jane B. Acri, PhD). Chair: (Larry D. Byrd, PhD).

11:00-11:50 am (Miller Room, Marriott)

New Fellows Address: Drug discrimination and dependence: What have we learned? (Charles P. France, PhD). Chair: (Alice M. Young, PhD).

SATURDAY, AUGUST 12

1:00-1:50 pm (Broadhurst Room, Marriott)

Invited Address: Evaluating drug effects on complex behavioral processes (Joseph M. Moerschbaecher, PhD). Chair: (John J. Boren, PhD).

2:00-3:50 pm (Wilder/Odets Room, Marriott)

Symposium: Learning and conditioning theory in the treatment of cocaine dependence. 1. Cognitive-behavioral relapse prevention treatment for cocaine dependence

(Kathleen Carroll, PhD). 2. Passive and active strategies for treating cocaine cue reactivity (Anna Rose Childress, PhD). 3. Voucher-based reinforcement of cocaine abstinence (Kenneth Silverman, PhD). 4. The matrix intensive outpatient model of stimulant abuse treatment (Rick Rawson, PhD). 5. Outpatient behavioral treatment for cocaine dependence (Stephen T. Higgins, PhD). Discussant (Charles P. O'Brien, MD, PhD). Chairs: (Stephen T. Higgins, PhD and Charles R. Schuster, PhD).

4:00-4:50 pm (Marquis Salon B, Marriott)

Division 28 Presidential Address: Misdirected hunters/gatherers: Shooting watermelon in psychopharmacology (John Grabowski, PhD). Chair: (Lewis Seiden, PhD).

5:00-5:50 pm (Marquis Salon B, Marriott)

Division 28 Business Meeting Chairs: (John Grabowski, PhD and Stephen C. Fowler, PhD).

SUNDAY, AUGUST 13

9:00-9:50 am (Marquis Salon A, Marriott)

New Fellows Address: Drugs of abuse and negative reinforcement (Mark Galizio, PhD). Chair: (Steven I. Dworkin, PhD).

10:00-10:50 am (Marquis Salon A, Marriott)

Paper Session I: Preclinical Studies in Psychopharmacology and Substance Abuse: 1. LSD: Place preference and taste avoidance, but not taste aversion (Linda A. Parker, PhD). 2. Stress and relapse to heroin-seeking behavior in rats (Yavin Shaham, PhD, Jennifer Puddicombe and Jane Stewart, PhD). 3. Social stressors and opioid self-administration in rats (Kelly J. Brown, BA, Laura C. Klein, BS, Matthew A. Rahman, BA and Neil E. Grunberg, PhD). 4. Matching-to-sample performance in monkeys exposed prenatally to cocaine (Kevin F. Schama, PhD, Leonard L. Howell, PhD, Larry D. Byrd, PhD and Paul J. Grimley, BS). Chair: (Linda A. Parker, PhD).

11:00-11:50 am (Marquis Salon A, Marriott)

New Fellows Address: Psychomotor stimulant self-administration by animal subjects: Pharmacological and behavioral mechanisms (William L. Woolverton, PhD). Chair: (Robert L. Balster, PhD).

2:00-3:50 pm (Sheraton Exhibition Center, Sheraton)

Poster Session and Social Hour: Psychopharmacology and Substance Abuse

Chair: (Suzette M. Evans, PhD). 1. NTB, a selective opioid antagonist, blocks cocaine's rewarding effects (Michael D. Chambers, BS, Kristopher L. Irizarry, Karen J. Boswell, PhD, Christopher L. Hubbell, PhD and Larry D. Reid, PhD). 2. NTB, a selective opioid antagonist, blocks nicotine's rewarding effects (Patricia M. Gonzales, BS, Gary W. Krupsky, Christopher L. Hubbell, PhD and Larry D. Reid, PhD). 3. The effects of diazepam and propranolol on punished schedule-induced polydipsia (Ricardo Pellon, PhD, Pilar Flores, PhD and Esmeralda Lamas, PhD). 4. Postnatal growth of rhesus monkeys exposed prenatally to cocaine (Kevin F. Schama, PhD, Leonard L. Howell, PhD, Larry D. Byrd, PhD and Adria J. Kitchens, BA). 5. Acoustic startle responses as predictors of fentanyl self-administration in rats (Kelly J. Brown, BA, Laura C. Klein, BS, Matthew A. Rahman, BA and Neil E. Grunberg, PhD). 6. Relapse of oral fentanyl self-administration in female and male rats (Laura C. Klein, BA, Eric J. Popke, BS and Neil E. Grunberg, PhD). 7. Sex differences in relationship of licit substance use and impulsivity (Tracy L. Waldeck, BA, Kenneth Thompson, BA, Clea C. Evans, BA, Sherry A. Burns, MA, Scott E. Miller, BS and L. Stephen Miller, PhD). 8. Mediators of tension-reduction expectancies: Anger expression, gender, and alcohol consumption (Celeste O. Milligan, BS, Tara Neavins, BA, and Vincent J. Adesso, PhD). 9. Alcohol expectancies: Effects of gender and family history of alcoholism (Leslie H. Lundahl, MS, Tania M. Davis, MA and Vincent J. Adesso, PhD). 10. Serotonin and alcohol intake in men with alcoholic family histories (David G. LeMarquand, BA, Chawki Benfelfat, MD, Simon N. Young, PhD).

(cont'd pg. 5)

Division 28 Program Schedule (cont'd)

Roberta M. Palmour, PhD and Robert O. Pihl, PhD). 11. Family history of alcoholism and alcohol-related problems: A connection? (Kristine A. Martin, BA and Vincent J. Adesso, PhD). 12. Typical drinking situations of high versus low anxiety sensitive subjects (Sherry H. Stewart, PhD and Sharon B. Zeitlin, PhD). 13. Analogue stress-induced drinking in high versus low anxiety sensitivity (Sherry H. Stewart, PhD and Sarah B. Samoluk, MA). 14. Posttraining alcohol enhances memory for Velten statements (Kenneth R. Bruce, BS, Edwin Poon, BA and Robert O. Pihl, PhD). 15. The development of the defensive drinker test (DDT) (Tania M. Davis, MA and Vincent J. Adesso, PhD). 16. Prospective differential prediction of adolescent substance use and problem use (Eric M. Stice, MA and Laurie Chassin, PhD). 17. Dispenser location influences condom taking in a cocaine treatment clinic (Danielle R. Carrigan, BA, Kimberly C. Kirby, PhD, Douglas B. Marlowe, JD, PhD and Jerome J. Platt, PhD). 18. Accelerated intake: Decreasing pre-treatment attrition in out-patient cocaine treatment (David S. Festinger, MA, Richard J. Lamb, PhD, Kimberly C. Kirby, PhD and Douglas B. Marlowe, JD, PhD). 19. Desipramine blood levels in bulimic women: Implications for treatment (Andrew R. Getzfeld, PhD). 20. Aberrant drug taking attitudes and behaviors in cancer patients (Steven D. Passik, PhD, Russell K. Portenoy, MD and William S. Breitbart, MD). 21. Licit substance use and depressive features in a non-clinical population (Kenneth A. Thompson, BA, Tracy L. Waldeck, BA, Scott E. Miller, BS, Clea C. Evans, BA, Sherry A. Burns, MA and L. Stephen Miller, PhD). 22. Differences between cigarette smokers and nonsmokers in cocaine-dependent outpatients (John M. Roll, PhD, Stephen T. Higgins, Alan J. Budney, PhD, Warren K. Bickel, PhD and Gary J. Badger, MD). 23. Human drug craving: Improving measurement (Edward G. Singleton, PhD, Stephen J. Heishman, PhD, Thomas E. Douglas, MEd and Jack E. Henningfield, PhD). 24. Development and validation of a caffeine related beliefs questionnaire (Mitchell L. Schare, PhD, Jeffrey I. Kassinove, BA and Ross M. Solomon, MA). 25. Caffeine effects on motor acquisition in a force discrimination

task (Scott E. Miller, BS, Theodora Papageorgiou, BA, Sherry A. Burns, MA, Clea C. Evans, BA and L. Stephen Miller, PhD). 26. Smoking research: Where to publish? (Anthony Liguori, PhD and John R. Hughes, MD).

Monday August 14

9:00-9:50 am (Gramercy/Herald Room, Marriott) **New Fellows Address:** Cocaine-opiate interactions in humans: Laboratory studies (Richard W. Foltin, PhD). Chair: (Marian W. Fischman, PhD).

10:00-11:50 am (Marquis Salon B, Marriott) **Paper Session II: Human Laboratory Studies in Psychopharmacology:** 1. Effects of tobacco deprivation on interaction between craving and attention (Sandra L. Bell, BA, Stephen J. Heishman, PhD, Edward G. Singleton, PhD and Jack E. Henningfield, PhD). 2. Caffeine abstinence: A residential laboratory study (Margaret J. Haney, PhD, Sandra D. Comer, PhD, Richard W. Foltin, PhD, Suzette M. Evans, PhD and Marian W. Fischman, PhD). 3. Changes in focused attention and associative encoding following diazepam ingestion (Gregory G. Brown, PhD, Jill B. Rich, PhD and Jennifer Simkins-Bullock, PhD). 4. Feedback on work performance affects amphetamine self-administration in humans (Sandra D. Comer, PhD, Margaret J. Haney, PhD, Richard W. Foltin, PhD and Marian W. Fischman, PhD). 5. Nicotine vapor inhaler: Abuse liability determination (Leslie M. Schuh, PhD, Kory J. Schuh, PhD, Jack E. Henningfield, PhD and Maxine L. Stitzer, PhD). 6. Psychophysiological effects of caffeine and stress on chronic caffeine consumers (Brooke E. Hillary, MA, Michell L. Schare, PhD, Paul Ingolia, MPharm, Susan Sabatino and Laura Cerone). 7. Alcohol and aggression and/or aggression and alcohol? (Jean-Marc Assaad, BA, Robert O. Pihl, PhD and Mark A. Lau, MSc). Chair: (Margaret J. Haney, PhD).

1:00-1:50 pm (Chealsea/Hudson Room, Marriott) **Invited Address:** Modulatory influences contributing to the behavioral effects of abused drugs (James E. Barrett, PhD). Chair: (Nancy A. Ator, PhD).

2:00-2:50 pm (Wilder/Odets Room,

Marriott) **New Fellows Address:** From molecule to medicine: Clinical research and risk management (Gilbert Honigfeld, PhD). Chair: (Nina R. Schooler, PhD).

Tuesday August 15

9:00-9:50 am (Booth/Edison Room, Marriott)

Invited Address: Substance abuse vulnerability in children of alcoholics (Mary E. McCaul, PhD). Chair: (Maxine L. Stitzer, PhD).

10:00-11:50 am (Kern/Sullivan Room, Marriott)

Symposium: Risk factors in substance abuse: Implications for treatment and management. 1. Risk factors in management of substance abuse and related problems (Steven L. Schandler, PhD). 2. Cognitive characteristics of individuals at risk for alcoholism (Vicki E. Pollock, PhD).

3. Personality and substance abuse (Mitch Earleywine, PhD). 4. Risk factors in adolescent substance abuse: Treatment and management implications (Connie S. Thomas, MA). 5. Importance of identifying and characterizing sub-types in substance abuse disorders (David Dorfman, PhD). Discus-sant (Michael J. Cohen, PhD).

Chair: Steven L. Schandler, PhD).

12:00-12:50 pm (Imperial Room, Marriott)

New Fellows Address: Use of drug blood levels in treating depression and psychosis (Carolyn M. Mazure, PhD). Chair: (Stephen C. Fowler, PhD)

1:00-1:50 pm (Alvin Room, Marriott)

Paper Session III: Clinical and Treatment Issues in Psychopharmacology: 1. Assessment of methadone treatment services as reinforcers (Mary Ann D. Chutuape, PhD, Kenneth Silverman, PhD and Maxine L. Stitzer, PhD). 2. Effects of cocaine abuse on the abuser's family/significant others (Kimberly C. Kirby, PhD, Douglas B. Marlowe, JD, PhD, Martin Y. Iguchi, PhD and Richard J. Lamb, PhD). 3. Readiness for treatment among cocaine, crack and opiate abusers (David Kressel, PhD and Gerald Melnick, PhD). 4. Personality differences as predictors of alcoholic consequences (Kevin L. Elliott, PhD). Chair: (Kimberly C. Kirby, PhD).

Council Representative Report, February 1995

Alice Young, Ph.D. Division 28 Council Representative

Council of Representatives met in open session on February 17, 18 and 19, 1995. The items that evoked the most discussion were 1) the proposed Division on Managed Health Care (defeated on a roll call vote of 29 in favor, 82 opposed, and 8 abstentions).

2) a Resolution on Public Information and Education, which authorizes the Board of Directors and the CEO to establish a special reserve fund of \$750,000 (the amount of a one-time surplus expected for 1995) to implement a 'comprehensive public relations campaign designed to educate and inform consumers' about psychological care, research, and services. The full plan is to be presented to Council in August 1995.

3) the proposed bylaw amendment to change the proportional voting requirements for seats on Council. This amendment would change the Association bylaws so that any Division, or State or Provincial Association would receive one Council seat for each 1% (rather than the current 5%) of the allocated votes. The legality of the proposed changes are currently under review by the District of Columbia Corporation Counsel. Because the time needed for that review is unknown, a Council vote on the bylaws amendment has been postponed until February 1996. However, Council passed a motion (in effect until the bylaws are put to a vote or August 1997, whichever is shorter) that:

- keeps current method of selecting and seating Council representatives unchanged, but
- provides expense reimbursement for one liaison-observer from any division or state not directly represented on Council, and
- encourages the APA president (who chairs the meeting) to give these liaison-observers full rights to speak on the floor of Council.

In other action, the Council approved permanent status for Division 50 (our sister Division of Addictions) and candidate status for Division 51 (Society for the Psychological Study of Men and Masculin-

ity). Council approved the report of the Commission for the Recognition of Specialties and Proficiencies in Professional Psychology, which sets a Commission, procedures and guidelines for guiding the process of specialization. Council also allocated funds from its '95 contingency fund to support two meetings of the BSA-sponsored Task Force on Scientific Perspectives of Intelligence Tests and Group Differences in Test Scores, to provide, among other things, a scientifically-based commentary on The Bell Curve controversy.

Of the new items introduced, all referred to various boards and/or committees, ones of particular importance to Division 28 include items - to set up a Task Force on Psychological Classification (with an apparent aim of supplanting DSM IV); - to automatically terminate the existence of any Division whose membership falls below 1.5% of the Association membership for two successive years.

SECOND ANNUAL CONFERENCE OF THE SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO (SRNT)

The second annual SRNT conference will be held March 15-16, 1996 at the Sheraton Washington Hotel in Washington DC.

A Call for Abstracts will be available from SRNT headquarters after 1 July 1995.

Deadline for receipt of abstracts is 15 November 1995.

For information about the meeting or membership, contact:

SRNT headquarters
103 South Adams Street Rockville MD
20850
(301) 251-2792.

Additional Information of Interest to Division 28 Members Regarding the 1995 Convention

Suzette Evans, Ph.D. Program Chair

Hospitality Suite and Social Hours:

We plan to host a hospitality suite for members and participants in Division 28 in the Marriott Hotel on Friday, Saturday and Sunday evenings. Details regarding the room number will be available at the time of the meeting. We are also co-sponsoring social hours with Divisions 1, 3, 6 and 25 on Friday and Saturday evenings from 5:00 to 7:00 pm so that individuals, particularly students, from different divisions can interact with one another.

Science Weekend Information:

The two themes for the 3 days of Science Weekend are "Emotion and Motivation" (Friday), and "Learning, Memory, and Cognition" (Saturday and Sunday). Division 28 has arranged with APA to have the Science Weekend program mailed directly to pre-registered members. Below I have listed some of the highlights of Science Weekend. Unfortunately, all of these sessions conflict with the Division 28 program.

Friday, August 11, 1995

10:00-11:50 am Symposium: Motivational Factors Related to Addictive Behaviors.

- The impact of positive and negative emotion on drug craving (Stephen T. Tiffany, PhD).
- Intoxication and hangover: When does the fun begin? (Frank A. Holloway, PhD and David Gauvin, PhD).
- "I'd walk a mile..." The behavioral economics of addiction (Warren K. Bickel, PhD). Chair: Richard W. Foltin, PhD.

Saturday, August 12, 1995

1:00-2:50 pm Symposium: Neuroimaging and Cognition.

- Brain activation during fMRI: Effects of working memory (Gregory McCarthy, PhD).
- Functional magnetic resonance imaging (fMRI): Methods and cognitive correlates (Bruce R. Rosen, PhD). Discussant: Patricia Goldman-Rakic, PhD. Chair: Max R. Trennery, PhD.

3:00-4:50 pm Symposium: The neuropsychology of AIDS.

1. Neurobehavioral effects of HIV-1 in infants and children: State of the art (Eileen B. Fennell, PhD). 2. Neurocognitive deficits and impairment in daily functioning associated with HIV (Robert A. Bornstein, PhD). 3. HIV associated neuropsychological impairment:

Update on progression and significance (Robert K. Heaton, PhD). Discussant/Chair: Yakov Stern, PhD.

Sunday, August 13, 1995

9:00-10:50 am Symposium: Models to Addictive Behaviors.

1. Early learning about drugs: Priming the pump for addictive behavior (Robert A. Zucker, PhD). 2. Harmonizing cognitive, biological, and psychosocial explanations of alcoholism (Mark S. Goldman, PhD). 3. Drug anticipation and drug addiction (Shepard Segal, PhD). 4. Relapse prevention and harm reduction: Areas of overlap (G. Alan Marlatt, PhD). Discussant: Bruce J. Overmier, PhD. Chair: Gregory T. Smith, PhD.

Action Alert!

When you get your ballot for APA Presidential voting, in the interest of voting for psychologists supportive of Division 28's mission, please designate Kurt Salizinger as your #1 vote and Richard Suinn as your #2 vote.

APA Continuing Education Workshop

Presented by Division 28

Co-sponsored by
Marion Merrell Dow

Workshop # 128

Cigarette Smoking: Practical Cessation Treatment Strategies

Sunday, August 13, 1995
9am to 5pm

Madison/East End Room, 4th Floor of
the Crowne Plaze Manhattan Hotel
1605 Broadway at 49th St. NY, NY

Cost: Members \$155 advanced registration, \$189 on site. Non-members \$175 advanced and \$200 on site.

For advanced registration call CE at:
1-800-374-2721

A Special Thanks to our Corporate Sponsors:

*Janssen Pharmaceuticals Inc.
E.I. DuPont de Nemours & Co.
Smith Kline Beecham Pharmaceuticals
Marion Merrell Dow Inc.
American Cyanamide Company
Eli Lilly and Company
Pfizer Incorporated
Wyeth-Ayerst Laboratories
Burroughs Wellcome Co.*

Positions Available

Established, independent
but team-oriented investigator

in Behavioral Neurotoxicology or Behavioral Pharmacology/Behavioral Genetics with research emphasis on toxic mechanisms relevant to occupational health is sought by growing multidisciplinary research institute focused on the brain and behavior. Start-up funds, competitive salaries (50% state-supported), and generous benefits package. Applications accepted until position filled; reviews to begin May 1, 1995.

Send CV, references, and a statement of research interests to:

W. Kent Anger, Chair
Behavioral Scientist Search Committee:
Center for Research on Occupational and
Environmental Toxicology
L606
Oregon Health Sciences University:
3181 SW Sam Jackson Park Rd.
Portland, OR 97201

*OHSU is an Equal Opportunity
Affirmative Action Employer.*

Behavioral Pharmacology of Substance Abuse

Johns Hopkins Medical School

Postdoctoral human research positions available in a stimulating and productive environment with excellent clinical and research resources. Develop, implement, and publish human laboratory research related to the behavioral, subjective, and physiological effects of psychoactive drugs. Special interest areas include: opioids, benzodiazepine anxiolytics/hypnotics, caffeine, nicotine dependence, drug discrimination, smoking cessation, drug abuse treatment. Experimental background and research experience required. Minorities encouraged. USPHS stipend levels based on experience. Send vita, letter interest, and name/phones of 3 references to George E. Bigelow, Ph.D., Roland R. Griffiths, Ph.D., or Maxine Stitzer, Ph.D.:

BPRU
Behavioral Biology Research Center
5510 Nathan Shock Drive
Johns Hopkins Bayview Campus
Baltimore, MD

Division 28 Officers:

Elected:

President	John G. Grabowski	8/93-8/96	jgrabows.UTMSMAIL@MSI66.MSU.UTH.TMC.EDU
President-elect	Stephen C. Fowler	8/94-8/97	fowler@falcon.cc.ukans.edu
Past President	Lewis S. Seiden	8/92-8/95	lew@DRUGS.BSD.UCHICAGO.EDU
Council Representative	Alice M. Young	2/94-1/97	USERGH06@WAYNEMTS
Members-at-Large	Deborah A. Cory-Slechta	8/92-8/95	slechta@enrmed.ROCHESTER.EDU
	James L. Sorensen	8/93-8/96	
	Harriet de Wit	8/94-8/97	hdew@midway.uchicago.edu

Appointed:

Program Chair, 1995	Suzette Evans	8/94-8/96	
Past Program Chair	Marilyn E. Carroll	8/93-8/95	mcarroll@STAFF.TC.UMN.EDU
Newsletter Editor	James P. Zacny	8/93-8/96	zacn@midway.uchicago.edu
ASPET/Neuroscience Liaison	Nancy Afor	8/93-8/96	afor@BPRU.UUCP.JHU.EDU
APA Public Affairs Liaison	George E. Bigelow	8/91-8/95	bigelow@BPRU.UUCP.JHU.EDU
APSLiaison	Donald A. Overton	8/91-8/95	doverton@VM.TEMPLE.EDU
Board of Scientific Affairs	Ronald W. Wood	8/92-8/95	wood@SFCUJ.MED.NYU.EDU
Centennial Officer	Herbert Barry	8/91-8/95	barry@VMS.CIS.PITT.EDU
CPDD Liaison	Dorothy Hatsukami	2/95-2/98	hatsu001@maroon.tc.umn.edu
Com. on Animal Research	Christine A. Sannerud	8/93-8/96	sannerud@justice.usdoj.gov
Com. on Continuing Ed.	Maxine L. Stitzer	8/92-8/95	mstitzer@BPRU.UUCP.JHU.EDU
Com. on Nomt. & Awards	Larry D. Byrd	8/91-8/95	peggy@RMY.EMORY.EDU
Committee on Prescript. Priv.	Marlyne Kilbey	8/91-8/95	MKILBEY@WAYNEST1
Corporate Liaison	James L. Howard	8/92-8/95	
Membership Chairs	Jed Rose	8/94-8/97	jerose@acpub.duke.edu
	Warren Bickel	8/91-8/95	warren.bickel@UVM.EDU
Neurobehavioral Tox. Com.	Deborah A. Cory-Slechta	8/93-8/96	slechta@enrmed.ROCHESTER.EDU
Public Information	Kenneth A. Perkins	8/92-8/95	kperkins@vms.cs.pitt.edu
Secretary	David M. Penetar	8/92-8/95	penetar@WRAR-EMH1.ARMY.MIL
Treasurer	Jack E. Henningfield	8/91-8/97	
Women's Network Rep.	Carolyn M. Mazure	8/93-8/96	mazure@BIOMED.MED.YALE.EDU

James P. Zacny
Editor, Division 28 Newsletter
Department of Anesthesia & Critical Care
MC4028
5841 S. Maryland Avenue
University of Chicago
Chicago, IL 60637



000010444951 F CS0 2629
 DR VICTOR G LATIES
 SCH OF MED
 UNIV OF ROCHESTER BOX EHSC
 ROCHESTER NY 14642